Genetic testing 'may be reasonable' in postmenopausal breast cancer

US study finds 3.6% of cases have a pathogenic gene

The prevalence of pathogenic variants in cancer susceptibility genes may be high enough to warrant testing in women who develop breast cancer after menopause, US researchers say.